The Lung Cancer Partnership estimates that lung cancer kills almost twice as many American women as breast cancer and more than three times as many men as prostate cancer annually. To date, due to the lack of a cost-effective early detection method, lung cancer is usually diagnosed late when treatment is typically not effective.

With the LuCED Test, based on output from VisionGate’s Cell-CT system, symptomatic and high-risk populations can be screened without exposure to radiation from x-ray CT or other potentially harmful chemicals or processes. This aids in early detection to help patients begin treatment from the onset for the best possible outcomes. The Cell-CT test is painless and non-invasive. A sample of phlegm produced in the lungs is obtained through a deep cough. The phlegm is then processed to evaluate the structure of cells with patented, proprietary 3D cell image processing technology.

This ground-breaking technology computes the true 3D internal structure of the cell. The 3D anatomy can be seen clearly and analyzed quickly for any signs of abnormality indicative with cancer cells.

For more information, contact VisionGate.